Trials / Completed
CompletedNCT00679445
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
A Feasibility Study to Evaluate the Safety And Tolerability of the EPI-RAD90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization (CNV) in Patients With Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- NeoVista · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.
Detailed description
Therapeutic advances in the arena of neovascular age-related macular degeneration (AMD) have provided multiple treatment options for the disease. Radiotherapy has been studied in multiple clinical trials in the past with many studies showing a therapeutic benefit. Treatment with radiotherapy and anti-VEGF compounds is a promising approach to treating AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NeoVista Ophthalmic System | A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2008-05-16
- Last updated
- 2011-07-27
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00679445. Inclusion in this directory is not an endorsement.